Episode 207: 5 Factors and Domains of Psychiatric Care
By listening to this episode, you can earn 1.75 Psychiatry CME Credits.
Other Places to listen: iTunes, Spotify
Article Authors: Joanie Burns, DNP, APRN, PMHNP-BC; Adam Borecky, MD; David Puder, MD
“Between stimulus and response there is a space. In that space is our power to choose our response. In our response lies our growth and our freedom.”
Introduction
The 5-factor approach to holistic, patient-centered psychiatric care takes into account that each individual who seeks care is unique in their physiological and psychological make-up and that there are multiple factors that influence both physical and mental health (for better or worse). While the serotonin theory and other neurochemical theories (aka “chemical imbalance” theories) continue to dominate pop-culture understandings of psychiatry, there is growing evidence that there are multiple causative factors for depression and other mental health diagnoses. Therefore, it is helpful to understand that various factors may be contributing to the presenting symptom(s) and to offer a multi-faceted approach that addresses these factors and alleviates the symptoms.
The 5-factor approach addresses four environmental factors (therapy, sleep, activity, and nutrition) that patients and their caregivers may choose to modify in order to improve overall well-being, as well as the option of including medication/s (the 5th factor). While therapy may not be considered a typical “environmental” factor, in some respects, as with modifying sleep, activity, and nutrition, a patient chooses to attend and participate in therapy and to implement the skills learned in therapy. Likewise, although to a lesser degree, the utilization of medications may be considered a pseudo-environmental factor in that patients make a conscientious/thoughtful choice to accept a medication option, fill the prescription, and take the prescription as directed. At times, this may include modifying or creating a schedule to maintain consistency with a medication regimen and, possibly, the addition of other activities to maintain or improve medication compliance, such as establishing a designated time each week to fill a pill sorter/organizer.
The 5-factor approach to treatment is based on the importance of sensorium and its pivotal role in regulating thoughts, feelings, and overall mental health. Sensorium is a lens to understand how we focus on various things. Sensorium is total brain function, which fluctuates throughout the day and depends on a number of factors, including sleep, stress levels, and more (Ep. 6; Ep. 9; Ep. 10; Ep. 11; Ep. 85; McLaughlin et al., 2007).
The 5 Factors
Therapy
Sleep
Activity
Nutrition
Medication/s
Psychotherapy
Given the heavy emphasis on psychopharmacologic/psychotropic interventions due to chemical imbalance theories, the benefits of psychotherapy and supportive therapeutic interactions are often downplayed or overlooked (Ahmad, 2023; Moncrieff et al., 2022). Additionally, many patients are under the impression that medications are a “quick fix.” Of note, the rate of prescribing medication increased dramatically during the COVID pandemic (Sanborn et al., 2023), and while the percentages of patients receiving any mental health treatment (including therapy) have also increased (Hasin & Grant, 2015; Terlizzi & Schiller, 2022), the prescribing of psychotropic medications remains the default treatment of choice for both providers and patients alike. There is a cultural factor as well, as Americans [in particular] may have “a large appetite for pharmacological treatments” (Kukreja et al., 2013), which may or may not be appropriate (Ep. 157). Simply put, too many patients are being prescribed medication without adjunctive psychotherapy or lifestyle changes (Mojtabai & Olfson, 2008). Because of these factors, mental health concerns are not being treated in the most effective way possible. This is especially the case when considering the treatment of psychological trauma, for which talk therapy can cure in ways medications cannot (Ep. 19; Fischer et al., 2022).
While there is evidence pointing to an increase in referrals for psychotherapy, in comparison to data regarding psychotropic prescribing, a wide discrepancy between referrals for these treatment modalities still exists. Notably, McKay and colleagues (2006) highlight how referrals for medication are numerous despite evidence that the “psychiatrist effect” shows more is happening in psychiatry than just medications (Ep. 168):
The proportion of variability in outcomes was due less to the treatment received than to the psychiatrist administering the treatment.
The person of the psychiatrist makes a difference in the response to antidepressant medication.
The health care community would be wise to consider the psychiatrist not only as a provider of treatment, but also as a means of treatment (McKay et al., 2006).
In one study on obsessive compulsive disorder (OCD), two groups of people were studied—those who underwent cognitive behavioral therapy, and those that took medication. The therapy was found to be as helpful in eliminating OCD symptoms. However, the OCD symptoms returned when the medication was stopped. The symptoms did not return when the person had received cognitive behavioral therapy (Baxter, et al., 1992; Ep. 19).
The positive influence of supportive therapeutic interactions is very apparent in the data from meta-analyses showing significant improvement/resolution of symptoms in patients receiving a placebo during medication trials. “Physicians' failure to establish good rapport with patients accounts for much of the ineffectiveness of care” (McKay et al., 2006). Further supporting the efficacy of therapy as an intervention is the recommendation for therapy (with or without psychotropic medication) in resources such as A Guide to Treatments That Work (Nathan & Gorman, 2015), Psychopharmacology Algorithms (Osser, 2021), Kaplan and Sadock's Synopsis of Psychiatry (Sadock et al., 2015), Psychopharmacology and Pregnancy (Galbally et al., 2014), and the recommendations developed by the United States Preventive Services Task Force (USPSTF) (Cheung et al., 2018; Siu & USPSTF, 2016; Siu et al., 2016), to name a few.
What do our patients gain from incorporating therapy into their treatment regimen?
Therapeutic interventions provide long-lasting change.
Learn new skills, behaviors, thought patterns
More robust than medication interventions for abating and resolving symptoms long term.
Expand support system/wellness team.
Is a specific therapeutic modality recommended?
Several studies have shown that the therapeutic relationship (rapport between patient and provider) has more bearing on symptom improvement than the modality of therapy employed (Ankarberg & Falkenström, 2008; Ep. 171; McKay et al., 2006; Wampold & Imel, 2015). In an article published in 2010, Dr. Shedler (Ep. 144) expands on this dynamic and highlights how the therapeutic relationship also impacts medication compliance and response to psychotropic medications. To further define and quantify the aspects of therapeutic rapport, Dr. Puder developed a metric called the Connection Index (CI) (Ep. 149; Puder et al., 2022). Utilizing the CI, he has shown how higher scores correlate with better outcomes in supervision (Ep. 149; Puder et al., 2022); other, similar studies have shown this for therapy (more immediate and long-term improvement).
A highly effective therapeutic modality called mentalization-based therapy (MBT) is discussed in “Psychiatry & Psychotherapy Podcast” ep. 205, where doctors Puder, Bateman, and Fonagy highlight the efficacy of MBT and long-duration therapy (Bateman & Fonagy, 2008; Bateman & Fonagy, 2013). Specifically, MBT has demonstrated significant potential to reduce the symptoms, distress, and severity of comorbidities, while increasing the quality of life and relationships in patients with borderline personality disorder (BPD) (Vogt & Norman, 2019).
Signs therapy is working:
Increased connection with others (Ep. 205; McWilliams, 2004)
Nancy McWilliams: the overall aspects of mental health include (Ep.171):
Sense of safety and trust in oneself, others, and the world
Sense of Agency
Sense of continuity
Self-esteem
Affect tolerance
Self-preservation and Altruism
Acceptance
Capacity to love, work, and play
Free will/self-regulation (the idea of self-efficacy improving and all the positive associated outcomes) (Baumeister, Crescioni, & Alquist, 2011; Ep. 84, Ep. 85, Ep. 86)
Increased vulnerability with the therapist (Ep. 205)
How Long Does Effective Therapy Take?
Dr. Shedler and co-author, psychologist Eric Gnaulati (2020), have also written on the question of how much time is needed for therapy to produce meaningful change. In this article, “The Tyranny of Time: How Long Does Effective Therapy Really Take?,” they present evidence that effective therapy takes significantly longer than the 8- to 16-week treatments often used in controlled trials (Ep. 144) (see also Bateman & Fonagy, 2008; Bateman & Fonagy, 2013; Ep. 205; Verheul et al., 2003).
Because of the incredibly difficult nature of studying psychotherapy, researchers typically chose shorter periods of time, 8- and 16-week trials, to study, but not on the basis of research that shows these are inherently beneficial time frames to begin with. Consequently, there are hundreds of studies on treating depression alone, all based on treatments of <16 sessions.
A recent large meta-analysis showed that CBT was effective at getting 20% of people into remission compared to wait list control. The reason it was only 20% is because the studies were short! The insurance companies would love for 12 sessions to be idealized as the “gold standard,” however, in clinical practice this is not enough to get the other 70-80% into remission!
A study of over 10,000 therapy clients, assessed session-to-session with a validated outcome instrument, found that it took 21 sessions or about six months of weekly therapy to see clinically significant changes in 50% of patients. Only after 40 sessions, or almost a year of weekly therapy, did researchers see significant changes in 75% of patients (Lambert et al., 2001). Research has also called into question the long-term efficacy of brief therapy (Shedler & Gnaulati, 2020). Yet brief manualized therapies are still frequently viewed as the standard of care, and most research on psychotherapy continues to focus on abbreviated therapy.
Multiple factors explain the continued predominance of brief therapy. One issue is a lack of communication between researchers and clinicians. Few studies have asked practicing therapists how long it takes for therapy to show significant effects, and when the question is asked, they find that practitioners generally see better results with long-term therapy. An Emory University survey of 270 experienced psychotherapists found that their last completed therapies “in which patient and therapist agreed that the outcome was reasonably successful” required a median of 52 to 75 sessions (Morrison et al., 2003).
Compared to brief therapy, long-term therapy is also simply less studied. Practical constraints are partly to blame: studies of long-term therapy are expensive, methodologically complex, and resource-intensive. But the relative lack of research on long-term therapy also creates a self-fulfilling prophecy: when “less-studied” is falsely equated to “less evidence-based”, it perpetuates the stereotype that long-form therapy is not evidence-based.
Dr. Shedler concludes that “real therapists operating in the real world recognize that therapy takes time and that people don’t come packaged with single DSM disorder categories. People are complex and there is a need to create a relationship with the patient over time. The actual schism is between practicing clinicians and researchers who operate in cognitive parallel universes” (Ep. 144).
The efficacy of therapy as an essential component of treatment is further exemplified by a study conducted by doctors Fonagy and Bateman (2008) that followed patients diagnosed with borderline personality disorder (BPD) 5 years after receiving 18 months of individual and group mentalization-based therapy through a partial hospitalization program and an additional 18 months of twice-weekly mentalization based group therapy. The study yielded statistically significant reductions in suicide attempts, emergency room utilization, quantity and duration of psychoactive medications, and the presence of symptoms that qualify for a diagnosis of BPD. Of specific interest, the treatment group, had a mean of 0.02 years of the 5 years of follow up on 3 or more drugs, where the treatment as usual had 1.9 years on 3 or more drugs, illustrating the impact of enough therapy on long-term outcomes with decreased need of medications.
One group of patients underwent either 18 months of intensive partial hospitalization mentalization-based treatment, at approximately 9 hours of therapy per week for a total of 648 treatment hours, while the other group underwent treatment as usual for BPD. The MBT group then continued with less intensive MBT groups twice a week for an additional 18 months (144 more treatment hours). The standard treatment group did not have any interventions after the initial 18 months. Then, both groups were followed for an additional 5 years without any further interventions.
Significant differences were found at the 18-month check-in, 36-month check-in, and the final 8 year check-in. Differences in the MBT vs. standard treatment groups were increased over the 5 year periods for each outcome (Bateman & Fonagy, 2008; Ep. 206).
Studies Show Psychotherapy Changes The Brain
All interventions that work to cure depression have a “final common pathway” of leading to positive brain changes via neuroplasticity changes, a marker of which is brain-derived neurotrophic factor (BDNF) and other neurotrophic factors.
Increase in BDNF when psychotherapy is combined with (an)other intervention(s).
A rise in BDNF levels was observed in depressive patients when psychotherapy was combined with medication. Patients with post-traumatic stress disorder (PTSD) who responded to therapy presented a raise in BDNF levels mostly when combined with physical activity. There was a rise in BDNF levels in those who responded to psychotherapy in patients with bulimia, in borderline patients, and in insomniacs (Claudino et al., 2020).
A PTSD study by Fischer, Schumacher, and Daniels (2022): “PTSD is characterized by specific neurobiological alterations, with preliminary findings indicating that at least some of these may normalize during psychotherapy.”
Sleep
Physical and cognitive/emotional functions rely on adequate sleep (Ep. 11). Therefore, regulating sleep helps modulate mood and physical wellbeing and is one of the few things that is easily modified and customized to fit our individual needs. Sleep is an essential component of mental health, so much so that changes in sleep are part of diagnostic criteria for depressive disorders, anxiety disorders, and many other psychiatric disorders (American Psychiatric Association; Ep. 65). Current studies have highlighted an alarming increase in reports of depression, anxiety, and suicidal ideation by persons of all ages, while recent studies regarding sleep are yielding data that point to an increasing trend of sleep deficit, which correlates with worsening physical and mental health.
Recommendations from the CDC and Sleep Foundation:
9-12 hours recommended for school-age children (6-12yo)
8-10 hours recommended for teens (13-18yo)
Significant phase for brain growth, development and connectivity
R/L brain connections finalizing (generally complete between ages 17-21yo)
7+ hours recommended for adults (CDC, 2022; Suni, 2022).
A dialogue about sleep:
What is your current sleep schedule?
What time do you go to bed?
How long does it take you to fall asleep?
Do you wake up during the night? If so, how often and are you able to fall back to sleep?
What time do you typically wake up for the day?
Do you feel refreshed when you wake?
Caffeine intake?
Exercise/activity before bed?
Sleep apnea (or other respiratory concerns)?
Medications or other substances that may impact sleep?
For problematic sleep:
To illustrate one new ominous destructive trend: increased screen time before bed.
Several studies have documented the link between nighttime screen use and disruption of sleep. Notably, a study conducted by Mireku et al. (2019) showed that:
Night-time phone and TV use has been associated with a higher likelihood of insufficient sleep (less than 8 hours) on both weekdays and weekends (OR = 1.32 & 95%CI[1.10,1.60]; OR = 1.40 & 95%CI[1.23,1.60] respectively).
Teens using mobile phones in a lighted room had a higher chance of getting insufficient sleep (OR = 1.32 & 95%CI[1.37,1.95]) and sleeping later (OR= 1.64 & 95%CI[1.37,1.95]) on weekends compared to non-users.
Those who used mobile phones in a dark room on weeknights were over 2x more likely to get insufficient sleep (OR=2.13 & 95%CI[1.79,2.54]) and over 3x more likely to go to sleep later (OR=3.38 & 95%CI[3.25, 4.62]) compared to non-users.
Using mobile phones at night was associated with lower quality of sleep compared to non use (β=-1.18 & 95%CI[-1.85,-0.52]).
Screen time during bedtime is even worse for mental health (more and more teens are texting throughout the night) (Hartley et al., 2022; Royant-Parola et al., 2022).
How To Change Sleep Habits
Provide patients with sleep hygiene tips (preferably in writing). There are open source tip sheets available online. One such resource is provided by the CDC: Tips for Better Sleep | CDC.
Often, if referring to a sleep specialist, patients will be asked the above questions and be advised to implement improved sleep hygiene practices with or without the aid of medications. For some patients, in the absence of a sleep wake disorder, sleep apnea, or other physiological problem causing sleep disruption, refining sleep habits (implementing some/most of the sleep tips) is a cost-effective and efficacious means to achieve consistent sleep on most nights.
Activity
Exercise has been found to have better compliance and less side effects when compared to pharmacological interventions, and may be used as a beneficial adjunct to traditional pharmacological methods (Ep. 8; Pajonk et al., 2010; Ströhle et al., 2015).
How does activity improve mood?
“Feel good” chemicals such as endorphins and dopamine are released during activity/exercise. There are other lesser known, but no less impactful, chemicals released during exercise (Hunsberger et al., 2009; Turner et al., 2020).
Contracting muscle acts as an endocrine organ (Ep. 165; Turner et al., 2020).
Brain derived neurotrophic factor (BDNF) is a growth factor for the hippocampus that is involved in cell survival, learning, and neurogenesis. Muscle contractions lead to the secretion of myokines cathepsin-B and irisin which cross the blood–brain barrier to indirectly increase BDNF (Oudbier et al., 2022).
Physical and emotional strength/resilience increase (Blumenthal et al., 2007).
Increased exposure to eustress (ex: gradual increase of weight training) over time increases overall physical and psychological resilience (Mucke et al., 2018).
Low muscle mass with poor mitochondrial health is associated with cognitive impairment. When mitochondria function is increased, there is potentially a higher capacity to weather stressors on a cellular level (Oudbier et al., 2022).
Improved sleep.
Thinking back to therapy fundamentals with the cognitive triangle and “feelings follow actions/behavior,” the goal would be to support patients in developing their own plan to implement positive/healthy activity(ies) that will promote wellness. This may mean helping a patient rewrite their internal negative script of “I can’t” or “It’s too hard” to “I can” or “I did it.” We like to use the analogy of baby steps and we remind patients that we are not asking/demanding CrossFit Extreme (for example), but one step toward the patient’s goal(s). Just as we get excited over the baby steps of a toddler, we can share that excitement for ourselves and with each other about the baby steps of growth/personal development we are experiencing from our applied efforts. Too often, we hear people discredit their work. In these instances, we strive to highlight the accomplishment and help the patient acknowledge what they have achieved and give themselves permission to take credit for their work. An example: “I only walked 5 minutes today” reframed as, “I walked 5 minutes today!”
There is evidence to support the efficacy of weight/strength training for improved mental health (Blumenthal et al., 2007; Ep. 10; Ep. 18; Ep. 96; Ep. 142; Ep. 165; Mucke et al., 2018). Again, this is not intended to imply that extreme activity/training is needed to achieve improvement. Taken in its purest sense, this is the gradual increase of strength exercises over time, building both physical and psychological resilience.
Nutrition
Nutrition also plays a role in mental health (Ep. 9, Ep. 59, Ep. 131; Jacka et al., 2017; Lane et al., 2022; Sánchez-Villegas et al., 2009). Of the 5 factors, this is the area that we typically receive the most pushback, often in the form of questions like: “What does food have anything to do with how I feel?” Simply put, what we eat matters, not only for physical well-being, but also for cognitive-emotional health. Take into consideration the proportion of the brain to the overall size of the body. This relatively small part of your body utilizes one-quarter of your daily caloric intake! Choosing healthy meal options equates to choosing clean (cleaner) fuel for the brain. Additionally, when we choose to eat (refuel) makes a difference, as well. Think about how we feel/act when we are hungry – not our best selves (“hangry” is a real thing) (Ep. 9).
Similar to the activity factor, the expectation is not for extreme or fad dieting. The goal is for well-rounded meals with appropriate proportions of micro and macro nutrients and making small, incremental changes versus an overnight dietary overhaul (remember…baby steps).
When is food going to give the biggest win?
Getting rid of unhealthy foods (ultra-processed foods), adding healthy foods, and learning to eat them mindfully made a significant difference in depression symptoms (Ep. 131; Ep. 187; Jacka et al., 2017; Lane et al., 2022).
A study of 10,094 participants found that diet impacted how many future depressive events took place (Ep. 131; Sánchez-Villegas et al., 2009).
Diet can potentially prevent future episodes of depression, with a particular value of increased fruits, nuts, high monounsaturated fatty acids (MUFAs) foods, and fish in moderation (Ep. 131; Sánchez-Villegas et al., 2009).
There are specific vitamins and minerals that are known to impact mental health (Ep. 59) when a deficiency is present. For example, low vitamin D (Lerner et al., 2018) and low folate (vitamin B-9) (Martone, 2018) are associated with depression, and low iron often causes fatigue, which mimics the anergia of depression.
Lack of omega-3 in the diet has been associated with depression and anxiety, according to research into the inflammatory processes that contribute to sub-optimum mental health (Ep. 131; Dighriri et al., 2022; Wenk, 2022). Additionally, adequate omega-3 has been attributed to reduced symptomatology of anxiety, attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), depression, and schizophrenia (Lange, 2020).
Getting omega-3 through whole foods (Cleveland Clinic, 2023; Dighriri et al., 2022) is important: chia seed, flax seed, salmon, walnuts, spinach, brussel sprouts, seaweed.
When considering/assessing dietary deficiencies, it may be helpful to obtain lab work or collaborate with the patient’s primary care provider (PCP), as in some cases, prescription repletion is needed versus relying on over-the-counter (OTC)-strength supplements.
A Role For Medication
There is a lot that can be said here, but the overarching concept, regardless of medication, is maintaining an open dialogue to foster a patient-centered team approach to care. This often entails acknowledging, by saying out loud, “I understand the medications, but you are the expert on you and your input is important,” as well as considering what the research/literature recommends and balancing this with how the patient feels about medication(s). One way to approach this is to emphasize that the recommendations are options, not mandates. This may be especially helpful for a patient who needs to feel that they have control over the process/autonomy over their person. With this in mind, the provider and patient work together to find the best fit for the patient: what will target symptoms, has the lowest side effect potential, and works with the patient's lifestyle/needs.
From a conservative approach, initiate medications “low and slow” and titrate to the lowest effective dose. While there are prescriptions available for just about everything, the goal is to utilize the least amount of medication possible (Ep. 19) and help to make this attainable by implementing any, or all, of the first 4 factors.
Alternatively, in a crisis situation there is a role for putting the fire out—making immediate and frequent changes to rapidly optimize medication efficacy and assist someone out of a very acute episode.
In Episode 19, Dr. Cummings uses a simple guideline to see if someone would benefit from medicine or talk therapy:
If what the person is depressed about is something in their lifestyle—their weight, job, relationship—lifestyle changes and talk therapy will probably be most effective.
If someone is experiencing neurovegetative symptoms of depression, such as: loss of appetite or increased appetite, severe energy loss, severe sleep disturbance with early morning awakening, physically slowed down, they are suffering from brain disturbances that are helped by medication.
Is Medication Forever?
Often, we are asked by patients if medication is forever. This may be one of the most difficult conversations to have with patients, as many patients do not want to hear that long term, or lifelong medication is needed and recommended. It may be helpful to approach the dialogue from a symptomology and/or diagnosis standpoint: “The experts have studied this thoroughly and find that people who have similar symptoms to what you are experiencing will need ____.” For example: single depressive episode = 4-9 months following stabilization according to the APA’s Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2017), while other sources recommend longer duration of psychotropic medication following point of remission (Shelton, 2001; Zwiebel & Viguera., 2022); recurrent anxiety or depression (specifically, 3+ episodes) = lifelong medication (Miller, 2013); obsessive-compulsive disorder (OCD), bipolar disorder, schizophrenia = lifelong medication (Ep. 19; Gitlin et al., 2001; Robinson et al., 1999). While it is preferable that patients hear us out and want to follow recommendations in order to avoid decompensation and maintain progress toward their goals, it is helpful to maintain a supportive and empathic “options, not mandates” approach, employing motivational interviewing (MI) (Ep. 199; Miller & Rollnick, 2023; Shea, 2017) and sharing resources from the Common Ground Program (Deegan, 2023) to support patient autonomy and their treatment goals.
Neuroleptic Discontinuation Study (Ep. 8):
Exacerbation or relapse was almost universal within 2 years in those who discontinued antipsychotics (Gitlin et al., 2001).
“Consistent evidence shows that neuroleptics, administered as a maintenance treatment, reduce relapse rates in schizophrenic patients. A comprehensive review that analyzed 66 studies found a mean cumulative relapse rate of 53% in patients withdrawn from neuroleptic therapy compared to 16% for those maintained on a regimen of neuroleptic therapy” (Gitlin et al., 2001).
“Robinson et al. (1999) found that patients who discontinued antipsychotic medications (not randomly assigned but self-selected) following at least 1 year of treatment relapsed at a rate almost five times that of those who continued taking medications over a 5-year period” (Gitlin et al., 2001).
Polypharmacy
There are times when patients are on numerous medications. Whether polypharmacy occurs intentionally or unintentionally, it is important to attempt a thorough medication reconciliation during each appointment and to eliminate redundancies, medication overlap, and medications that complicate/hinder the wellness process (Ep. 19; Ep. 157). “Pill burden” and side effects are often-cited reasons for discontinuing medications. Therefore, striving to utilize the lowest effective dose of the fewest medications is an important aspect not only from a physiological standpoint but also for improving long term medication compliance.
Read et al. (2017): Polypharmacy increased, and in some cases doubled, the risk of adverse effects. The total number of psychotropics was correlated with progressive risk of adverse effects, and was inversely correlated to perceived efficacy of the drugs (Ep. 157).
There are several types of polypharmacy. Read et al.’s (2017) definition of polypharmacy, several drugs in multiple classes, is a common one. Further elaborating on polypharmacy, Kukreja et al. (2013) explain there are other ways to define the issue. Polypharmacy can refer to redundancy with multiple drugs in the same class. Adjuvant polypharmacy refers to the use of one drug to treat the adverse effects of another. Polypharmacy through augmentation occurs when one drug’s dose is maximized, but symptoms remain. In these cases, another agent is added to continue to pursue a treatment effect. Additionally there is total polypharmacy, the absolute number of medications regardless of class, mechanism, and indication (Ep. 157; NASMHPD Technical Report, 2001).
Do Psychotropic Medications Hurt the Brain?
The first thing to know is that significant depression (Duman & Aghajanian, 2012; Songco et al., 2023; Vialou et al., 2013), bipolar, and schizophrenia (Ep. 8) hurt the brain (Soloey-Nilsen et al., 2022). It seems there is a bidirectional aspect, that both having depression leads to higher rates of things like dementia, but also having a stroke, or some type of brain disease, leads to higher rates of depression (Ep. 155).
How can we tell if the brain is hurt? One marker is brain-derived neurotrophic factor (BDNF), which is one of the most studied neurotrophins in the healthy and diseased brain. As a result, there is a large body of evidence that associates BDNF with neuronal maintenance, neuronal survival, plasticity, and neurotransmitter regulation. Patients with psychiatric and neurodegenerative disorders often have reduced BDNF concentrations in their blood and brain. A current hypothesis suggests that these abnormal BDNF levels might be due to the chronic inflammatory state of the brain in certain disorders, as neuroinflammation is known to affect several BDNF-related signaling pathways” (Lima-Giacobbo et al., 2018). SSRIs and ketamine increase BDNF (Bjorkholm & Monteggia, 2015) (so does exercise, as noted in the prior section on exercise/activity). Additionally, some neuroleptic (aka antipsychotic) medications have been found to slow/prevent BDNF reductions, which would otherwise lead to more severe symptomatology and chronicity of symptoms (Bartolomeis et al., 2022).
Without treatment, the majority of mental health symptoms tend to become more severe and more pervasive over time (Severe et al., 2020). With this, symptoms become more difficult to treat. This often correlates with the need for more invasive treatments, such as stronger medications at higher doses and, when appropriate, electroconvulsive therapy (ECT) (Ep. 152). Appropriately applied psychotropic treatment protects the brain from the inflammatory processes that take place during psychological (and physical) stress (symptom exacerbation), which cause measurable brain damage (destruction of neurotransmitters and loss of gray matter) and prevent healing between episodes (Bartolomeis et al., 2022; Bjorkholm & Monteggia, 2015; Hunsberger, et al., 2009; Lima-Giacobbo et al., 2018).
In several episodes of Dr. Puder’s “Psychiatry & Psychotherapy Podcast,” guest presenters explain the neuro-protective benefit of specific medications, the damage that occurs to the brain in the absence of adequate treatment, as well as the significant reduction in suicidality offered by some medications (specifically lithium and clozapine) (Ep. 8, Ep. 49, Ep. 58, Ep. 152, Ep. 190).
It is also crucial to understand how psychiatric disorders alone can cause severe cognitive effects (Ep. 8; Ep. 155; Vialou et al., 2013). Major depressive disorder, as mentioned above, has been associated with significant memory loss and cognitive impairment due to the disruption of metabolic activity in the brain. This is termed pseudodementia, a clinical picture that mimics dementia where patients complain of memory loss. Schizophrenia and bipolar disorder have also been shown to cause severe cognitive impairments (Ep. 152).
Often Overlooked: Lithium, Clozapine and Long-acting Injectables (LAIs)
Lithium and clozapine are often overlooked treatments despite a long history of proven effectiveness (Ep. 57; Ep. 58; Lin et al., 2020; Mahli et al., 2023). This trend has led to a dearth of providers who offer these medications as treatment options, where significant provider gaps/disparities have developed in areas where there is a greater patient need for these medications than there are providers available/willing to prescribe and monitor these medications. For example, there are often limited outpatient providers who prescribe and monitor these medications outside of the resources offered by county and state level mental health clinics.
In episodes 57 and 58, Dr. Cummings and Dr. Brown highlight how lithium is highly effective in treating depression, bipolar I, and significantly reducing suicidality (Lewitzka et al., 2015; Song et al., 2017). Additionally, a study by Pompili et al. (2023) cites lower rates of hospitalization in patients treated with lithium. Lithium may be initiated with a loading dose of 600 mg at bedtime (once a day dosing at bedtime puts less strain on renal function) (Ep. 58). Baseline lab work is needed prior to initiating lithium, especially assessing thyroid and renal function. Lithium serum levels are then needed 3-5 days after initiating or increasing the dose and every 3-6 months once on a stable dose.
In episode 190, Dr. Kane emphasizes the unmatched effectiveness of clozapine for treating schizophrenia (Correll et al., 2022) and bipolar disorder. It is highly recommended as a treatment option if a patient fails prior trials of neuroleptic medications (Gammon et al., 2021). Clozapine is the only FDA-approved psychotropic medication for treating treatment-resistant schizophrenia (Ep. 190; Nathan & Gorman, 2015). A systematic quantitative meta-review by Wager et al. (2021) highlights that “even though clozapine is considered one of the most effective medications and is listed in the WHO ‘Model List of Essential Medicines,’ there is frequently a delay in clozapine initiation, leading to poorer mental health and functional outcomes, preceded by attempts of polypharmacy treatment without evidence for effectiveness.” There is evidence to support initiating clozapine after failure of one antipsychotic versus two (Kahn et al., 2018). Studies indicate that if a patient has failed 2 medications, clozapine worked roughly 30% of the time (Nathan & Gorman, 2015; Siskind, Siskind, & Kisely, 2017).
Historically, clozapine has been associated with an increased risk of agranulocytosis (also known as neutropenia), which is low white blood cells and may lead to infection/s. More recent findings indicate that the risk is significantly lower than previously documented (Goldani et al., 2022). However, due to the past-reported risk of developing neutropenia, all patients who are initiated on clozapine (within the U.S.) must be registered in the Clozapine REMS program.
Long-acting injectables (LAIs) have proven to be a game changer in the world of psychiatry and the treatment of chronic mental health disorders such as bipolar disorder and schizophrenia. LAIs provide a safe treatment option for patients, providers, and caregivers who seek to reduce pill burden, the need to remember daily oral doses, and maintain consistent medication serum levels over time (Ep. 190; Kane et al., 2020). LAIs are now offered in 30-, 60-, 90-, and a recently launched 120-day intervals (depending on medication) and are easily administered intramuscularly (IM).
For patients who are not fully responding to treatment, there is a lot of nuance in learning to monitor blood levels of antipsychotics which can give you information (Ep. 127; Meyer & Stahl, 2021).
A Note on THC – a significant roadblock to achieving optimized mental health
While the legalization of THC-containing products is expanding, the availability of information for the general public about the negative effects of THC consumption is significantly lacking. THC use is linked to: increased anxiety, apathy, depression, increased risk for psychotic episodes, lower IQ (and that of offspring), increased risk of opioid addiction (and that of offspring) (Ep. 44, Ep. 45, Ep. 64, Ep. 68, Ep. 183, Ep. 184, Yale Med & CDMHA, n.d.).
Simply put, THC utilization interferes with the effectiveness of each of the 5 above mentioned factors.
It impedes the therapeutic process by instilling apathy to change and blunts the ability to process emotions and develop healthy coping mechanisms.
It disrupts sleep.
It tends to make persons apathetic toward physical activity.
It is associated with increased appetite (“munchies”), which often manifests as cravings for unhealthy snacks.
It limits medications from binding to neurotransmitters and therefore limits the efficacy of medications. It also increases the side effects of medication (especially weight gain).
If THC is not purchased from a licensed dispensary, the potency of THC can vary greatly and is often not known (NIDA, 2022; USDOJ, 2014). Additionally, THC bioavailability varies widely depending on how the THC is consumed—inhalation, oral/edible, topical/transdermal, other (intranasal, rectal) (O’Brien & Blair, 2021). There are also concerns associated with intake of substances that are laced into THC products such as methamphetamines, cocaine, and opioids including fentanyl, as well as contaminants such as heavy metals, fungi, and bacteria.
Resources
Ahmad, S. (2023, March 10). Why Depression Treatments Sometimes Fail. Psychology Today. https://www.psychologytoday.com/ca/blog/balanced/202303/why-depression-treatments-fail
American Psychiatric Association (APA). (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, D.C.: American Psychiatric Association.
American Psychiatric Association (APA) (2017). Treating major depressive disorder; A Quick Reference. Psychiatry.org. 2010. https://www.apa.org/depression-guideline/guideline.pdf
Ankarberg, P., & Falkenström, F. (2008). Treatment of depression with antidepressants is primarily a psychological treatment. Psychotherapy: Theory, Research, Practice, Training, 45(3), 329–339. https://doi.org/10.1037/a0013309
Bartolomeis, A., Barone, A., Begni, V., & Riva, M. A. (2022). Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective. Pharmacological Research, 176. https://doi.org/10.1016/j.phrs.2022.106078
Bateman, A., & Fonagy, P. (2008). 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. The American journal of psychiatry, 165(5), 631–638. https://doi.org/10.1176/appi.ajp.2007.07040636
Bateman, A., & Fonagy, P. (2013). Mentalization-Based Treatment. Psychoanalytic inquiry, 33(6), 595–613. https://doi.org/10.1080/07351690.2013.835170
Baumeister, R.F., Crescioni, A.W. & Alquist, J.L. Free Will as Advanced Action Control for Human Social Life and Culture. Neuroethics 4, 1–11 (2011). https://doi.org/10.1007/s12152-010-9058-4
Baxter, L. R., Schwartz, J. M., Bergman, K. S., Szuba, M. P., Guze, B. H., Mazziotta, J. C., Alazraki, A., Selin, C. E., Huan-Kwang, F., Munford, P., & Phelps, M. E. (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of general psychiatry, 49(9), 681-689. doi:10.1001/archpsyc.1992.01820090009002
Björkholm, C., & Monteggia, L. M. (2016). BDNF - a key transducer of antidepressant effects. Neuropharmacology, 102, 72–79. https://doi.org/10.1016/j.neuropharm.2015.10.034
Blumenthal, J. A., Babyak, M. A., Doraiswamy, P. M., Watkins, L., Hoffman, B. M., Barbour, K. A., Herman, S., Craighead, W. E., Brosse, A. L., Waugh, R., Hinderliter, A. & Sherwood, A. (2007). Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosomatic medicine, 69(7), 587–596. https://doi.org/10.1097/PSY.0b013e318148c19a
Centers for Disease Control and Prevention(CDC). (2022, September 19). Are you Getting Enough Sleep? National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. https://www.cdc.gov/sleep/features/getting-enough-sleep.html
Centers for Disease Control and Prevention(CDC). (2022, September 13). Tips for Better Sleep. National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. https://www.cdc.gov/sleep/about_sleep/sleep_hygiene.html
Cheung, A. H., Zuckerbrot, R. A., Jensen, P. S., Laraque, D., & Stein, R. E. K. (2018). Guidelines for adolescent depression in primary care (GLAD-PC): Part II. Treatment and ongoing management. Pediatrics, 141(3), 1-16. https://doi.org/10.1542/peds.2017-4082
Claudino, F.C.A., Gonçalves, L., Schuch, F.B., Martins, H.R.S., & Rocha, N.S. (2020). The Effects of Individual Psychotherapy in BDNF Levels of Patients With Mental Disorders: A Systematic Review. Front. Psychiatry, 11:445. doi: 10.3389/fpsyt.2020.00445
Cleveland Clinic. (2023). Omega-3 Fatty Acids. https://my.clevelandclinic.org/health/articles/17290-omega-3-fatty-acids
Clozapine REMS (Risk Evaluation and Mitigation Strategy). (n.d.) Retrieved from: https://www.newclozapinerems.com/home#
Correll, C. U., Agid, O., Crespo-Facorro, B., de Bartolomeis, A., Fagiolini, A., Seppälä, N., & Howes, O. D. (2022). A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS drugs, 36(7), 659–679. https://doi.org/10.1007/s40263-022-00932-2
Deegan, P. (2023). Medication Empowerment (commongroundprogram.com).
Common Ground Program. https://www.commongroundprogram.com/medication-empowerment
Dighriri, I. M., Alsubaie, A. M., Hakami, F. M., Hamithi, D. M., Alshekh, M. M., Khobrani, F. A., Dalak, F. E., Hakami, A. A., Alsueaadi, E. H., Alsaawi, L. S., Alshammari, S. F., Alqahtani, A. S., Alawi, I. A., Aljuaid, A. A., & Tawhari, M. Q. (2022). Effects of Omega-3 Polyunsaturated Fatty Acids on Brain Functions: A Systematic Review. Cureus, 14(10), e30091. https://doi.org/10.7759/cureus.30091
Duman, R. S. & Aghajanian, G. K. (2012). Synaptic Dysfunction in Depression: Potential Therapeutic Targets. Science, 338,68-72. DOI:10.1126/science.1222939
Fischer, S., Schumacher, S., & Daniels, J. (2022). Neurobiological Changes in Post-Traumatic Stress Disorder and Their Reversibility by Psychotherapy. Zeitschrift für Klinische Psychologie und Psychotherapie*, 51 (2). Doi:https://doi.org/10.1026/1616-3443/a000650
Fonagy, P., & Bateman, A. (2008). The development of borderline personality disorder--a mentalizing model. Journal of personality disorders, 22(1), 4–21. https://doi.org/10.1521/pedi.2008.22.1.4
Galbally, M., Snellen, M., & Lewis, A. (2014). Psychopharmacology and pregnancy: Treatment efficacy, risks, and guidelines. New York, NY: Springer.
Gammon, D., Cheng, C., Volkovinskaya, A., Baker, G. B., & Dursun, S. M. (2021). Clozapine: Why Is It So Uniquely Effective in the Treatment of a Range of Neuropsychiatric Disorders?. Biomolecules, 11(7), 1030. https://doi.org/10.3390/biom11071030
Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G. & Aravagiri, M. (2001). Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. American Journal of Psychiatry, 158(11), 1835-1842. DOI: 10.1176/appi.ajp.158.11.1835
Goldani, A. A. S., Rabelo-da-Ponte, F. D., Feiten, J. G., Lobato, M. I. R., Belmonte-de-Abreu, P. S., & Gama, C. S. (2022). Risk of neutropenia among clozapine users and non-users: results from 5,847 patients. Revista brasileira de psiquiatria (São Paulo, Brazil : 1999), 44(1), 21–25. https://doi.org/10.1590/1516-4446-2021-1765
Hartley, S., Royant-Parola, S., Zayoud, A., Gremy, I., & Matulonga, B. (2022). Do both timing and duration of screen use affect sleep patterns in adolescents?. PloS one, 17(10), e0276226. https://doi.org/10.1371/journal.pone.0276226
Hasin, D. S. & Grant, B. F. (2015). The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol., 50(11):1609-40. doi: 10.1007/s00127-015-1088-0
Hunsberger, J., Austin, D. R., Henter, I. D., & Chen, G. (2009). The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues in clinical neuroscience, 11(3), 333–348. https://doi.org/10.31887/DCNS.2009.11.3/jhunsberger
Jacka, F. N., O’Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M. L., Brazionis, L., Dean, O. M., Hodge, A., M., & Berk, M. (2017). A randomised-controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Med. 15(23). https://doi.org/10.1186/s12916-017-0791-y
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020). Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. JAMA psychiatry, 77(12), 1217–1224. https://doi.org/10.1001/jamapsychiatry.2020.2076
Kahn, R. S., van Rossum, I. W., Leucht, S., McGuire, P., Lewis, S. W., Leboyer, M., Arango, C., Dazzan, P., Drake, R., Heres, S., Díaz-Caneja, C. M., Rujescu, D., Weiser, M., Galderisi, S., Glenthøj, B., Eijkemans, M. J. C., Fleischhacker, W. W., Kapur, S., & Sommer, I. E. (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry, 5(10):797-807. https://doi.org/10.1016/S2215-0366(18)30252-9
Kukreja, S., Kalra, G., Shah, N., & Shrivastava, A. (2013). Polypharmacy in psychiatry: a review. Mens Sana Monogr. 11(1), 82-99. doi: 10.4103/0973-1229.104497
Lambert, M. J., Hansen, N. B., & Finch, A. E. (2001). Patient-focused research: Using patient outcome data to enhance treatment effects. Journal of Consulting and Clinical Psychology, 69(2), 159–172. https://doi.org/10.1037/0022-006X.69.2.159
Lane, M. M., Gamage, E., Travica, N., Dissanayaka, T., Ashtree, D. N., Gauci, S., Lotfaliany, M., O’Neil, A., Jacka, F. N., & Marx, W. (2022). Ultra-processed food consumption and mental health: A systematic review and meta-analysis of observational studies. Nutrients, 14(13), 2568. https://doi.org/10.3390/nu14132568
Lange, K. (2020). Omega-3 fatty acids and mental health. Global Health Journal, 4(1). 18-30. https://doi.org/10.1016/j.glohj.2020.01.004.
Lerner, P. P., Sharony, L., & Miodownik, C. (2018). Association between mental disorders, cognitive disturbances and vitamin D serum level: Current state. Clinical nutrition ESPEN. 23, 89–102. https://doi.org/10.1016/j.clnesp.2017.11.011
Lewitzka, U., Severus, E., Bauer, R., Ritter, P., Müller-Oerlinghausen, B., & Bauer, M. (2015). The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review. International journal of bipolar disorders, 3(1), 32. https://doi.org/10.1186/s40345-015-0032-2
Lima-Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019). Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Molecular neurobiology, 56(5), 3295–3312. https://doi.org/10.1007/s12035-018-1283-6
Lin, Y., Mojtabai, R., Goes, F. S., & Zandi, P. P. (2020). Trends in prescriptions of lithium and other medications for patients with bipolar disorder in office-based practices in the United States: 1996-2015. Journal of affective disorders, 276, 883–889. https://doi.org/10.1016/j.jad.2020.07.063
McKay, K. M., Imel, Z. E., & Wampold, B. E. (2006). Psychiatrist effects in the psychopharmacological treatment of depression. Journal of affective disorders, 92(2-3), 287–290. https://doi.org/10.1016/j.jad.2006.01.020
McLaughlin, K. J., Gomez, J. L., Baran, S. E., & Conrad, C. D. (2007). The effects of chronic stress on hippocampal morphology and function: an evaluation of chronic restraint paradigms. Brain research, 1161, 56–64. https://doi.org/10.1016/j.brainres.2007.05.042
McWilliams, N. (2004). Psychoanalytic psychotherapy: A practitioner's guide. Guilford Press. https://www.guilford.com/books/Psychoanalytic-Psychotherapy/Nancy-McWilliams/9781593850098
Malhi, G.S., Bell, E., Jadidi, M., Gitlin, M., & Bauer, M. (2023). Countering the declining use of lithium therapy: a call to arms. Int J Bipolar Disord, 11(30) . https://doi.org/10.1186/s40345-023-00310-x
Martone, G. (2018). Enhancement of recovery from mental illness with l-methylfolate supplementation. Perspectives in psychiatric care. 54(2), 331–334. https://doi.org/10.1111/ppc.12227
Meyer, J. M., Stahl, S. M. (2021) The Clinical Use of Antipsychotic Plasma Levels. In: The Clinical Use of Antipsychotic Plasma Levels: Stahl’s Handbooks. Stahl’s Essential Psychopharmacology Handbooks. Cambridge University Press. https://doi.org/10.1017/9781009002103
Miller, J. J. (2013). Discontinuing Medications: When, Why, and How-to. Psychiatric Times, 30(7). https://www.psychiatrictimes.com/view/discontinuing-medications-when-why-and-how
Miller, W. R., & Rollnick, S. (2023). Motivational Interviewing: Helping People Change and Grow. Guilford Publications. https://www.guilford.com/books/Motivational-Interviewing/Miller-Rollnick/9781462552795
Mireku, M. O., Barker, M. M., Mutz, J., Dumontheil, I., Thomas, M. S. C., Röösli, M., Elliott, P., & Toledano, M. B. (2019). Night-time screen-based media device use and adolescents' sleep and health-related quality of life. Environment International. 124. 66-78. https://doi.org/10.1016/j.envint.2018.11.069
Mojtabai, R., & Olfson, M. (2008). National patterns in antidepressant treatment by psychiatrists and general medical providers: Results from the National Comorbidity Survey Replication. The Journal of Clinical Psychiatry, 69(7), 1064–1074. https://doi.org/10.4088/JCP.v69n0704
Moncrieff, J., Cooper, R.E., Stockmann, T. et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry (2022). https://doi.org/10.1038/s41380-022-01661-0
Morrison, K.H., Bradley, R., & Westen, D. (2003). The external validity of controlled clinical trials of psychotherapy for depression and anxiety: A naturalistic study. Psychology and Psychotherapy: Theory, Research and Practice. 76, 109-132. https://doi.org/10.1348/147608303765951168
Mücke, M., Ludyga, S., Colledge, F., & Gerber, M. (2018). Influence of Regular Physical Activity and Fitness on Stress Reactivity as Measured with the Trier Social Stress Test Protocol: A Systematic Review. Sports Med 48, 2607–2622. https://doi.org/10.1007/s40279-018-0979-0
Nathan, P. E. and Gorman, J. M. (Eds.) (2015). A guide to treatments that work (4th ed.). New York, NY: Oxford University Press. https://psycnet.apa.org/record/2015-21466-000
National Association of State Mental Health Program Directors (NASMHPD). (2001): Technical Report on Psychiatric Polypharmacy. https://nasmhpd.org/sites/default/files/TechnicalReportFinal.pdf
National Institute on Drug Abuse (NIDA) (2022). Cannabis Potency Data. Retrieved from: https://nida.nih.gov/research/research-data-measures-resources/cannabis-potency-data
O’Brien, K., & Blair, P. (2021). Routes of Administration, Pharmacokinetics and Safety of Medicinal Cannabis. In: Medicinal Cannabis and CBD in Mental Healthcare. Springer, Cham. https://doi.org/10.1007/978-3-030-78559-8_11
Olfson, M., & Marcus, S. C. (2009). National patterns in antidepressant medication treatment. Archives of general psychiatry, 66(8), 848-856. doi:10.1001/archgenpsychiatry.2009.81
Osser, D. N. (2021). Psychopharmacology Algorithms: Clinical Guidance from the Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Residency Program. Philadelphia: Wolters Kluwer.
Oudbier, S. J., Goh, J., Looijaard, S. M. L. M., Reijnierse, E. M., Meskers, C. G. M., & Maier, A. B. (2022). Pathophysiological Mechanisms Explaining the Association Between Low Skeletal Muscle Mass and Cognitive Function. The journals of gerontology. Series A, Biological sciences and medical sciences, 77(10), 1959–1968. https://doi.org/10.1093/gerona/glac121
Pajonk, F., Wobrock, T., Gruber, O., Scherk, H., Berner, D., Kaizl, I., Kierer, A., Muller, S., Oest, M., Meyer, T., Backens, M., Schneider-Axmann, T., Thornton, A. E., Honer, W. G., & Falkai, P. (2010). Hippocampal Plasticity in Response to Exercise in Schizophrenia. Arch Gen Psychiatry, 67(2):133–143. doi:10.1001/archgenpsychiatry.2009.193
Pompili, M., Berardelli, I., Sarubbi, S., Rogante, E., Germano, L., Sarli, G., Erbuto, D., & Baldessarini, R. J. (2023). Lithium treatment versus hospitalization in bipolar disorder and major depression patients, Journal of Affective Disorders, 340, 245-249. https://doi.org/10.1016/j.jad.2023.08.028
Psychiatry & Psychotherapy Podcast Episode 006:Sensorium Part 1: Total Brain Function Optimization
Psychiatry & Psychotherapy Podcast Episode 009: Diet Optimization for Cognitive Function and Brain Optimization
Psychiatry & Psychotherapy Podcast Episode 010: Sensorium Part 3: Exercise as a Prescription for Depression, Anxiety, Chronic Stress (like Diabetes) and Sensorium
Psychiatry & Psychotherapy Podcast Episode 011: Sensorium Part 4: Medications, Drugs (THC, Alcohol), Medical Issues, Sleep, and Free Will
Psychiatry & Psychotherapy Podcast Episode 018: Prescribing Strength Training for Depression
Psychiatry & Psychotherapy Podcast Episode 019: How Psychiatric Medications work with Dr. Cummings
Psychiatry & Psychotherapy Podcast Episode 044: Marijuana and Mental Health
Psychiatry & Psychotherapy Podcast Episode 045:Schizophrenia in Film and History
Psychiatry & Psychotherapy Podcast Episode 049: Clozapine for Treatment Resistant Schizophrenia
Psychiatry & Psychotherapy Podcast Episode 057: Why Lithium is a Great Option for Treating Bipolar, with Dr. Walter A. Brown
Psychiatry & Psychotherapy Podcast Episode 058: Lithium Indications, Mechanism, Monitoring, & Side Effects
Psychiatry & Psychotherapy Podcast Episode 059: Which Foods are Good for Mental Health?
Psychiatry & Psychotherapy Podcast Episode 084: Free Will in Psychiatry & Psychotherapy Part 1
Psychiatry & Psychotherapy Podcast Episode 085: Free Will in Psychiatry & Psychotherapy Part 2
Psychiatry & Psychotherapy Podcast Episode 086: Free Will in Psychiatry & Psychotherapy Part 3
Psychiatry & Psychotherapy Podcast Episode 096: The Best Exercise Program for Depression
Psychiatry & Psychotherapy Podcast Episode 131: Diet to Treat Depression and Anxiety
Psychiatry & Psychotherapy Podcast Episode 142: Exercise as a Drug for Mental Health and Longevity
Psychiatry & Psychotherapy Podcast Episode 149: Connection Index
Psychiatry & Psychotherapy Podcast Episode 152: ECT Efficacy and Controversies with Dr. Cummings
Psychiatry & Psychotherapy Podcast Episode 155: Is Depression a Chemical Imbalance?
Psychiatry & Psychotherapy Podcast Episode 157: Polypharmacy in Psychiatry
Psychiatry & Psychotherapy Podcast Episode 165: Exercise for the Brain
Psychiatry & Psychotherapy Podcast Episode 187: Best Diet For Mood Update 2023
Psychiatry & Psychotherapy Podcast Episode 199: Motivational Interviewing with William Miller
Puder, D., Dominguez, C., & Borecky, A. (2022). Assessing Interpersonal Relationships in Medical Education: the Connection Index. Acad Psychiatry 46, 683–691 (2022). https://doi.org/10.1007/s40596-021-01574-0
Read, J., Gee, A., Diggle, J., & Butler, H. (2017). The interpersonal adverse effects reported by 1008 users of antidepressants; and the incremental impact of polypharmacy. Psychiatry Res. 256:423-427. doi: 10.1016/j.psychres.2017.07.003
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., & Lieberman, J. A. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry; 56:241-247. doi:10.1001/archpsyc.56.3.241
Royant-Parola, S., Londe, V., Tréhout, S., & Hartley, S. (2018). Nouveaux médias sociaux, nouveaux comportements de sommeil chez les adolescents [The use of social media modifies teenagers' sleep-related behavior]. L'Encéphale, 44(4), 321–328. https://doi.org/10.1016/j.encep.2017.03.009
Sadock, B. J., Sadock, V. A., & Ruiz, P. (2015). Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry (11th ed.). Philadelphia, PA: Wolters Kluwer.
Sanborn, M., Ali, M. M., & Creedon, T. B. (2023). National trends in psychotropic medication prescribing before and during the COVID-19 pandemic. Psychiatry research, 325, 115248. https://doi.org/10.1016/j.psychres.2023.115248
Sánchez-Villegas, A., Delgado-Rodríguez, M., Alonso, A., Schlatter, J., Lahortiga, F., Majem, L. S., & Martinez-Gonzalez, M. A. (2009). Association of the Mediterranean Dietary Pattern With the Incidence of Depression: The Seguimiento Universidad de Navarra/University of Navarra Follow-up (SUN) Cohort. Arch Gen Psychiatry. 66(10):1090–1098. doi:10.1001/archgenpsychiatry.2009.129
Severe, J., Gredon, J. F., & Priyanka, R. (2020). Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe? FOCUS. 18(2):120-128. https://doi.org/10.1176/appi.focus.20200008
Shea, S. C. (2017). Psychiatric interviewing: The art of understanding (3rd ed.). New York, NY: Elsevier.
Shedler, J. (2010). The Efficacy of Psychodynamic Psychotherapy. American Psychologist. (65)2. 198-109. https://pubmed.ncbi.nlm.nih.gov/20141265/
Shedler, .J. & Gnaulati, E. (2020, March/April). The Tyranny of Time: How Long Does Effective Therapy Really Take? PsychotherapyNetworker. https://www.psychotherapynetworker.org/article/tyranny-time
Shelton, R. C. (2001). Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy. Prim Care Companion J Clin Psychiatry, 3(4):168-174. doi: 10.4088/pcc.v03n0404
Siskind, D., Siskind, V., & Kisely, S. (2017). Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 62(11), 772–777. https://doi.org/10.1177/0706743717718167
Siu, A. L., and the US Preventive Services Task Force (USPSTF). (2016). Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 315(4):380–387. doi:10.1001/jama.2015.18392
Siu, A. L., in collaboration with the USPSTF. (2016). Screening for depression in children and adolescents: U. S. Preventive Services Task Force recommendation statement. Pediatrics, 137(3).1-8. doi: 10.7326/M15-2957
Soloey-Nilsen, H., Nygaard-Odeh, K., Kristiansen, M.G. Brekke, O. L., Mollnes, T. E., Reitan, S. K., & Oiesvold, T. (2022). Association between brain-derived neurotropic factor (BDNF), high-sensitivity C-reactive protein (hs-CRP) and psychiatric symptoms in medicated and unmedicated patients. BMC Psychiatry, 22(84). https://doi.org/10.1186/s12888-022-03744-2
Song, J., Sjölander, A., Joas, E., Bergen, S. E., Runeson, B., Larsson, H., Landén, M., & Lichtenstein, P. (2017). Suicidal behavior during lithium and valproate treatment: A within-individual 8-year prospective study of 50,000 patients with bipolar disorder. The American Journal of Psychiatry, 174(8), 795-802. https://doi.org/10.1176/appi.ajp.2017.16050542
Songco, A., Patel, S. D., Dawes, K., Rodrigues, E., O'Leary, C., Hitchcock, C., Dalgleish, T., & Schweizer, S. (2023). Affective working memory in depression.Emotion, 23(6), 1802–1807. https://doi.org/10.1037/emo0001130
Ströhle, A., Schmidt, D. K., Schultz, F., Fricke, N., Staden, T., Hellweg, R., Priller, J., Rapp, M. A., & Rieckmann, N. (2015). Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 23(12), 1234–1249. https://doi.org/10.1016/j.jagp.2015.07.007
Suni, E. (2023, March 22). How Much Sleep Do We Really Need? Sleep Foundation. https://www.sleepfoundation.org/how-sleep-works/how-much-sleep-do-we-really-need
Terlizzi, E. P. & Schiller, J. S. with the National Center for Health Statistics (NCHS). (2022). Mental Health Treatment Among Adults Aged 18–44: United States, 2019–2021. NCHS Data Brief No. 444. Retrieved from: https://www.cdc.gov/nchs/products/databriefs/db444.htm
Turner, A. I., Smyth, N., Hall, S. J., Torres, S. J., Hussein, M., Jayasinghe, S. U., Ball, K., & Clow, A. J. (2020). Psychological stress reactivity and future health and disease outcomes: A systematic review of prospective evidence. Psychoneuroendocrinology. (114). https://doi.org/10.1016/j.psyneuen.2020.104599
US Department of Justice (USDOJ) (2014). What You Should Know About Marijuana Concentrates: THC Extractions. Drug Enforcement Agency (DEA) Publications: https://www.dea.gov/sites/default/files/resource-center/Publications/marijuana-concentrates.pdf
US Preventive Services Task Force (USPSTF). (2022). Screening for Anxiety in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 328(14):1438–1444. doi:10.1001/jama.2022.16936
US Preventive Services Task Force (USPSTF). (2022). Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 328(15):1534–1542. doi:10.1001/jama.2022.16946
University of Mississippi (n.d.). Marijuana Research. The Marijuana Project. Retrieved from: https://pharmacy.olemiss.edu/marijuana/about/
Verheul, R., van den Bosch, L. M. C., Koeter, M. W. J., de Ridder, M. A. J., Stijnen, T., & van den Brink, W. (2003). Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. The British Journal of Psychiatry, 182(2), 135-140
Vialou, V., Feng, J., Robison, A. J., & Nestler, E. J. (2013). Epigenetic mechanisms of depression and antidepressant action. Annual review of pharmacology and toxicology, 53, 59–87. https://doi.org/10.1146/annurev-pharmtox-010611-134540
Vogt, K. S., & Norman, P. (2019). Is mentalization-based therapy effective in treating the symptoms of borderline personality disorder? A systematic review. Psychology and psychotherapy, 92(4), 441–464. https://doi.org/10.1111/papt.12194
Wagner, E., Siafis, S., Fernando, P., Falkai, P., Honer, W. G., Röh, A., Siskind, D., Leucht, S., & Hasan, A. (2021). Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. Transl Psychiatry 11, 487. https://doi.org/10.1038/s41398-021-01613-2
Wampold, B. E., & Imel, Z. E. (2015). The great psychotherapy debate: The evidence for what makes psychotherapy work (2nd ed.). Routledge/Taylor & Francis Group. https://psycnet.apa.org/record/2008-07548-000
Wenk, G. (2022). The Impact of Omega-3 on Mental Health: Can anti-inflammatory diets alter the onset of psychosis? Psychology Today. https://www.psychologytoday.com/intl/blog/your-brain-food/202201/the-impact-omega-3-mental-health
Yale School of Medicine & Connecticut Department of Mental Health and Addiction. (n.d). Cannabis and Psychosis Fact Sheet. Retrieved from: https://medicine.yale.edu/psychiatry/step/early-intervention-services/cannabis%20use%20and%20psychosis_380524_284_53825_v2.pdf
Zwiebel, S. J., & Viguera, A. C. (2022). Discontinuing antidepressants: Pearls and pitfalls. Cleveland Clinic Journal of Medicine, 89(1), 18-26. https://doi.org/10.3949/ccjm.89a.21020
*Journal of Clinical Psychology and Psychotherapy